Vir’s hepatitis delta combo tamps down virus as Gilead showdown looms

Vir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.